An extension phase II study of the clinical and biologic effects of docetaxel (Taxotere) in patients with locally advanced breast cancer.
Phase of Trial: Phase II
Latest Information Update: 04 Feb 2013
At a glance
- Drugs Docetaxel (Primary) ; Cyclophosphamide; Doxorubicin
- Indications Advanced breast cancer
- Focus Pharmacogenomic; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 04 Feb 2013 Status changed from active, no longer recruiting to discontinued as reported by Clinicaltrials.gov.
- 24 Jan 2012 Planned end date changed from 1 Dec 2013 to 1 Jan 2012 as reported by ClinicalTrials.gov.